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Abstract: Neuronal differentiation appears to be dependent on oxidative phosphorylation capacity.
Several drugs inhibit oxidative phosphorylation and might be detrimental for neuronal differentiation.
Some pregnant women take these medications during their first weeks of gestation when fetal
nervous system is being developed. These treatments might have later negative consequences on the
offspring’s health. To analyze a potential negative effect of three widely used medications, we studied
in vitro dopaminergic neuronal differentiation of cells exposed to pharmacologic concentrations
of azidothymidine for acquired immune deficiency syndrome; linezolid for multidrug-resistant
tuberculosis; and atovaquone for malaria. We also analyzed the dopaminergic neuronal differentiation
in brains of fetuses from pregnant mice exposed to linezolid. The drugs reduced the in vitro oxidative
phosphorylation capacity and dopaminergic neuronal differentiation. This differentiation process
does not appear to be affected in the prenatally exposed fetus brain. Nevertheless, the global DNA
methylation in fetal brain was significantly altered, perhaps linking an early exposure to a negative
effect in older life. Uridine was able to prevent the negative effects on in vitro dopaminergic neuronal
differentiation and on in vivo global DNA methylation. Uridine could be used as a protective agent
against oxidative phosphorylation-inhibiting pharmaceuticals provided during pregnancy when
dopaminergic neuronal differentiation is taking place.
Keywords: oxidative phosphorylation; xenobiotics; linezolid; uridine; neuronal differentiation;
Parkinson’s disease
1. Introduction
Late-onset Parkinson’s disease (PD) is a medical condition characterized by non-motor and
motor signs. Motor signs are essentially due to the loss of dopaminergic neurons in the substantia
nigra. These cells differ from less vulnerable neurons by having a higher basal rate of oxidative
phosphorylation (OXPHOS) [1]. OXPHOS is the main energy provider to power neuronal activity [2].
Although PD is currently understood as a multietiological and multifactorial condition [3], numerous
observations suggest that an OXPHOS defect may be a pathogenic event in many cases of PD [4]. Thus,
activities and levels of OXPHOS complexes were found to decrease in patients’ substantia nigra [4].
Thirteen OXPHOS system polypeptides (7, 1 and 3 from respiratory complexes I-CI, III-CIII and
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IV-CIV (abbreviations of respiratory complex I, III and IV are CI, CIII and CIV as already indicated),
respectively, and 2 from ATP synthase-CV), along with 2 rRNAs and 22 tRNAs required for their
expression, are encoded by the mitochondrial DNA (mtDNA). Very interestingly, levels of mtDNA
deletions and point mutations were higher, and the mtDNA copy number was lower, in substantia
nigra neurons of PD patients [5–7].
Many studies indicate that OXPHOS function is important, not only for mature neuronal
function, but also for neuronal differentiation [8,9]. In fact, OXPHOS-related mutant genes reduce
neuronal differentiation [10]. Some chemicals that are foreign to human beings, i.e., xenobiotics,
bind mtDNA-encoded proteins or RNAs and affect OXPHOS function. If OXPHOS function were
important for neuronal differentiation, these xenobiotics would negatively affect neurogenesis,
as shown for CI, CIII, CIV and CV inhibitors [9,11–13]. Several OXPHOS inhibitor pesticides
affect dopaminergic neurogenesis and increase the risk of PD [14]. However, it is not easy to
know when, how long and what concentrations people have been exposed to these xenobiotics.
On the other hand, this information is usually available for other OXPHOS xenobiotics, such as
some pharmaceutical drugs, although unconscious exposures are also possible [15]. Some of these
compounds can secondarily affect the respiratory complex activities, mitochondrial translation or
replication and, finally, cell differentiation. In fact, we have previously found that ribosomal antibiotics
and nucleoside reverse transcriptase inhibitors (NRTIs) diminish adipocyte differentiation of adipose
tissue-derived stem cells (hASCs) [16,17].
It has been proposed that decreased neurogenesis would be a key player for PD [18]. If altered
neurogenesis is related to PD and OXPHOS function is critical for neurogenesis, then the exposure to
OXPHOS xenobiotics might be a risk factor for developing PD [4]. Here we analyzed the effect on
dopaminergic neuronal differentiation of three widely used drugs with side effects on the OXPHOS
function. In the search for strategies to reverse their adverse consequences, we found that uridine,
a necessary compound for cell proliferation of OXPHOS-dysfunctional cells [19], prevented these
negative effects on dopaminergic neuronal differentiation.
2. Materials and Methods
2.1. Cells, Mice and Materials
The neuroblastoma SH-SY5Y cell line with mtDNA (rho+ cells) was obtained from Sigma (St. Louis,
MO, USA) (catalogue number 94030304, lot 13C014, P 17). The neuroblastoma SH-SY5Y rho0 cells,
without mtDNA, were a gift of Dr. Anne Chomyn from Prof. Attardi’s laboratory at the California
Institute of Technology. Another neuroblastoma SH-SY5Y rho0 cell line was generated in our laboratory
by 3 months exposure to 10 µg/mL ethidium bromide [20]. Human neural stem cells (hNSCs),
H9-derived, were from (Gibco®, Life TechnologiesTM, Carlsbad, CA, USA).
Seven-week-old C57BL/6J mice were purchased from Charles River Laboratories. Mice were
housed in standard polypropylene cages and maintained under controlled room temperature and
humidity with 12:12 h light-dark cycle. Food and water were available ad libitum.
Dulbecco’s Modified Eagle’s Medium (DMEM), DMEM/F-12 medium, fetal bovine serum (FBS),
StemPro Neural Supplement, recombinant human fibroblast growth factor-basic (FGFb), recombinant
human epidermal growth factor (EGF), L-glutamine, CellStart substrate, and phosphate buffered saline
(PBS) were from (Gibco®, Life TechnologiesTM, Carlsbad, CA, USA).
Retinoic acid (RA), phorbol 12-myristate 13-acetate (TPA), uridine, atovaquone (ATO),
azidothymidine (AZT), linezolid (LIN), 4′,6-diamidino-2-phenylindole (DAPI), paraformaldehyde and
Triton X-100 were acquired from (Sigma-Aldrich, St. Louis, MO, USA).
Polymerase chain reaction (PCR) primers, TaqMan® gene expression assays, TaqManTM MicroRNA
Reverse Transcription Kit and TaqMan® miRNA assays were from (Thermo Fisher Scientific, Waltham,
MA, USA). QuikChangeTM Site-Directed Mutagenesis Kit was obtained from (Stratagene, CA, USA).
Direct-zolTM RNA MiniPrep was from (Zymo Research, Irvine, CA, USA).
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Rabbit anti-POLG (mitochondrial DNA polymerase gamma), rabbit anti-UQCRFS1 (ubiquinol-
cytochrome c reductase, Rieske iron-sulfur polypeptide 1), mouse anti-p.MT-CO1 (OxPhos CIV
subunit I), rabbit anti-SDHA (succinate dehydrogenase A) and secondary antibodies DyLightTM were
from (Thermo Fisher Scientific, Waltham, MA, USA). Rabbit anti-MRPS12 (mitochondrial ribosomal
protein S12), rabbit anti-TH (tyrosine hydroxylase), mouse anti-β-ACTIN, rabbit anti-β-ACTIN, rabbit
anti-DAT (dopamine transporter), mouse anti-MAP2 (microtubule-associated protein 2) were from
(Sigma-Aldrich, St. Louis, MO, USA). Rabbit anti-TUBB3 (βIII-tubulin), rabbit anti-NSE (neuron-specific
enolase), rabbit anti-DCX (doublecortin), mouse anti-NES (nestin) and mouse anti-total OXPHOS
human WB antibody cocktail were purchased from (Abcam, Cambridge, UK). Super Signal West Pico
Chemiluminescence Substrate was from (Thermo Fisher Scientific, Waltham, MA, USA). Alexa Fluor®
488 and 594 were from (Molecular Probes, Eugene, OR, USA).
MethylFlashTM Methylated DNA Quantification Kit (Epigentek, Farmingdale, NY, USA).
Dopamine/noradrenaline ELISA kit (Rocky Mountain Diagnostics, Colorado Springs, CO, USA).
Amplex Red Acetylcholine/Acetylcholinesterase Assay Kit (Gibco®, Life TechnologiesTM, Carlsbad,
CA, USA).
2.2. Cell Culture and Differentiation
SH-SY5Y cells were cultured in DMEM high glucose (25 mM), 4 mM L-glutamine, and 1 mM
sodium pyruvate and supplemented with 10% FBS. SH-SY5Y rho0 cells were supplemented with
200 µM uridine. hNSCs (<10 passages) were grown in KnockOutTM DMEM/F-12 medium containing
StemPro Neural Supplement (2%), FGFb (20 ng/mL), EGF (20 ng/mL) and L-glutamine (2 mM), prior
to attachment on cell culture plates coated with CellStart.
Dopaminergic differentiation of SH-SY5Y cells was induced following optimized protocols [21].
To make cells more dependent on OXPHOS function, SH-SY5Y rho+ cells were differentiated in 5 mM
galactose media instead of 25 mM glucose. SH-SY5Y rho0 cells were differentiated in 25 mM glucose
and supplemented with 200 µM uridine. Dopaminergic differentiation of hNSCs was performed as
previously described [22].
Cells were maintained at 37 ◦C in a humidified atmosphere of 5% CO2. Cell number was
determined with trypan blue stain using a Countess Automated Cell Counter (Invitrogen, Thermo
Fisher Scientific, Waltham, MA, USA).
2.3. Pharmacological Treatments
For neuronal differentiation in the presence of xenobiotics, SH-SY5Y cells were exposed to AZT
(5 µM), LIN (40 µM) or ATO (0.5 µM). These drugs were dissolved in ethanol 100%. Final ethanol
concentration in the media did not exceed 0.025%.
AZT is used to treat the acquired immune deficiency syndrome (AIDS) because it inhibits the
human immunodeficiency virus (HIV) reverse transcriptase. However, it also affects human POLG,
and mtDNA replication. Thus, OXPHOS function is a common off-target of NRTIs toxicity [23].
For AZT, the current recommendations for adult patients call for 300 mg every 12 h. This dose is
approximately equivalent to 10 mg/kg/day, and results in a steady-state serum AZT concentration of
0.8 µM and peak concentrations (Cmax) of around 5 µM AZT [24].
LIN is a ribosomal antibiotic used in the treatment of multidrug-resistant tuberculosis (MDR-TB)
because inhibits the bacterial ribosome. However, it also inhibits mitochondrial protein translation.
The protein synthesis apparatus of mitochondria is similar to that of bacteria because of its endosymbiotic
origin and, therefore, mitochondrial ribosomes are frequently unintended off-targets of these ribosomal
antibiotics used in clinical practice to fight pathogenic bacteria. These antibiotics can provoke serious
adverse drug reactions in patients [25]. The LIN dose used in clinical practice is 600 mg every 12 h.
This dose results in steady-state peak serum concentrations of 44.5–80 µM [26].
ATO is used against Plasmodium falciparum, the parasite that causes malaria, and other parasites
causing opportunistic AIDS infections. Interspecies differences in the drug target, the coenzyme Q
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outer pocket (Qo site), have allowed its use against the parasites with few adverse effects on humans.
We had previously proposed that genetic variation in the human p.MT-CYB subunit from CIII would
generate structurally different Qo sites that also affect xenobiotics binding [27]. In fact, it has been
recently reported that a yeast model harboring a human haplogroup-defining Qo site variant increased
ATO sensitivity [28]. Moreover, this drug also inhibited CIII activity and oxygen consumption in
human cell lines [29]. The ATO dose used in clinical practice is 750 mg every 12 h. This dose generates
average blood concentrations around 40 µM [30]. We chose a low concentration because we noted that
concentrations higher than 1 µM had a very important effect on oxygen consumption of SH-SY5Y cells.
2.4. Cell Proliferation
SH-SY5Y cells were seeded on 100 mm plates (1 × 105 cells) and treated with AZT, LIN or ATO at
concentrations of 5, 10 and 0.5 µM, respectively. Cells were exposed to drugs for 7 days. Then, whole
cell lysates were obtained using radioimmunoprecipitation assay (RIPA) buffer. Protein concentration
was determined by the Bradford protocol (Bio-Rad, Hercules, CA, USA).
2.5. Overexpressing OXPHOS-Related Mutant Proteins
POLG, MRPS12 and UQCRFS1 constructs were obtained and introduced in the SH-SY5Y cells
using a lentiviral system [31]. We chose these proteins because they participate in the same
mitochondrial processes than the previously cited OXPHOS xenobiotics (replication—POLG and AZT,
translation—MRPS12 and LIN, and respiratory chain function—UQCRSF1 and ATO). POLG (RefSeq
NM_002693; NP_002684), MRPS12 (RefSeq Variant 1 NM_021107.1; NP_066930.1) and UQCRFS1
(RefSeq NM_006003; NP_005994) were PCR amplified with following primers:
POLG Fw: GTTTAAACGCCACCATGAGCCGCCTGCTCT and Rv: GGATCCCTATGGTCC
AGGCTGG;
MRPS12 Fw: GTTTAAACGCCACCATGTCCTGGTCTGGCC and Rv: GTTTAAACTGTTTATT
AAAACCCC;
UQCRFS1 Fw: GTTTAAACGCCACCATGTTGTCGGTAGCATCCCG and Rv: GGATCCTTAA
CCAACAATCACCATATCGTCACTGG.
A sequence checked clone was used as template for site directed mutagenesis by using
QuikChange® Site-Directed Mutagenesis Kit and the mutagenic primers following:
POLG Fw: CTACGGCCGCATCTGTGGTGCTGGGCAGC and Rv: GCTGCCCAGCACCACAG
ATGCGGCCGTAG; MRPS12 Fw: CTGTGCACGTTTACCCTCAAGCCGAAGAAGCC and Rv:
GGCTTC TTCGGCTTGAGGGTAAACGTGCACAG and UQCRFS1 Fw: GCACTCATCTTGGCTCTG
TACCCATTGCAAATGC and Rv: CGTGAGTAGAACCGAGACATGGGTAACGTTTACG.
Overexpressed variants of these genes were sequenced from retro-transcribed cellular RNA with
the same primers used for cloning.
2.6. Chromosomes and Mitochondrial DNA Analysis
Nuclear genetic fingerprint, karyotyping, mtDNA sequencing and mtDNA levels were
determined according to protocols previously reported [16,32]. For mtDNA sequencing, long-PCR
reactions were carried out in 50 µL reaction mixture containing 25 µL of 2X Phusion Master
Mix with GC Buffer (Thermo Fisher Scientific), 1 µL (0.5 µM) of each primer (MT-ND2-L:
5′-TTAATCCCCTGGCCCAACCCGTCATCTACTC-3′ and MT-ND2-H: 5′-CGGATACAGTTCAC
TTTAGCTACCCCCAAGTG-3′), 22 µL of sterile distilled H2O and DNA template (100 ng). The reaction
consisted of an initial denaturing step at 98 ◦C for 30 s, followed by 30 cycles of denaturing at 98 ◦C for
10 s, extension at 72 ◦C for 8 min 15 s, and a final extension at 72 ◦C for 10 min.
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2.7. DNA Methylation Analysis
For quantitative determination of 5-methylcytosine (5-mC) percentage in genome of mouse
brain samples, the MethylFlashTM Methylated DNA Quantification Kit was used following the
manufacturer’s instructions.
2.8. RT-qPCR Analysis
POLG, MRPS12 and UQCRFS1 mRNA levels were determined, in SH-SY5Y cells, by quantitative
PCR assays that were carried out in a LightCycler 2.0 system (Roche), using FastStart DNA MasterPLUS
SYBR Green I (Roche) and primers qMRPS12-36 Fw: AGGCAGCCACTCATGGATT, qMRPS12-36
Rv: GGCTTAATAGTGGTCCTGATGG, qPOLG#5 Fw: ACGCCCATAAACGTATCAGC, qPOLG#5 Rv:
CATAGTCGGGGTGCCTGA, qUQCRFS1#30 Fw: CCTGTGTTGGACCTGAAGC and qUQCRFS1#30
Rv: ATAACAAACAGAAGCAGGGACAT, respectively. The mRNA levels of subunits 2 and 6
(MT-ND2, MT-ND6) from CI, of peroxisome proliferator-activated receptor gamma (PPARG), and 12S
rRNA amount were determined and normalized using the 18S rRNA levels [16,32].
Total RNA, including microRNA, was isolated from the whole brain of each embryo using
the Direct-zolTM RNA MiniPrep according to the manufacturer’s instructions. Thirty ng of RNAs
were used for reverse transcription using the TaqManTM MicroRNA Reverse Transcription Kit
following the manufacturer’s instructions. Relative quantification of mRNA expression was
performed by TaqMan real-time PCR using the commercial probes described below, according
to the manufacturer’s protocol. Probes were as follows: Engrailed-1, En 1 (Mm00438709_m1);
paired-like homeodomain transcription factor 3, Pitx3 (Mm01194166_g1); and nuclear receptor-related
1, NURR1 (or Nr4a2) (Mm00443060_m1) and human glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (Mm99999915_g1). The samples were normalized with GAPDH. Individual TaqMan®
miRNA assays were used to quantify the mouse brain samples-expressed miRNAs (Mature miRNA
Sequences: mmu-miR-124a-3p, UAAGGCACGCGGUGAAUGCC; mmu-miR-132-3p, UAACAGUC
UACAGCCAUGGUCG; mmu-miR-133b-3p, UUUGGUCCCCUUCAACCAGCUA). The mouse brain
samples were normalized with snoRNA202.
2.9. Western Blotting
Western blot (WB) was used to determine protein levels in whole-cell lysates obtained using
RIPA buffer. Samples were resolved on sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) minigels (Miniprotean, Bio-Rad, Hercules, CA, USA) and were transferred to
polyvinylidene difluoride (PVDF) membranes (Trans-Blot® TurboTM Mini PVDF Transfer Pack,
Bio-Rad) using a Trans-Blot® TurboTM Blotting System (Bio-Rad). Membranes were analyzed by
immunoblotting with the following antibodies: rabbit anti-POLG (1:500), rabbit anti-MRPS12 (1:2000),
rabbit anti-UQCRFS1 (1:1500) and rabbit anti-β-ACTIN (1:4,000), rabbit anti-TUBB3 (1:1000), rabbit
anti-NSE (1:1000), rabbit anti-DCX (1 µg/mL), rabbit anti-TH (1:200), rabbit anti-DAT (1:200), mouse
anti-MAP2 (1:500), mouse anti-β-ACTIN (1:1000), mouse anti-p.MT-CO1 (1:1000) and rabbit anti-SDHA
(1:1000). After washing, the membrane was incubated with peroxidase-conjugated secondary antibodies
(1:5000 or 1:10000) for 1 h at room temperature or with appropriate secondary antibodies DyLightTM
(1:15000). Bands were visualized with Super Signal West Pico Chemiluminescence Substrate from
PIERCE® or using Odyssey® CLx Imaging System (LI-COR Biosciences, Lincoln, NE, USA).
2.10. Flow Cytometry
For flow cytometry (FC) analysis, cell suspensions were fixed with 4% paraformaldehyde for
15 min at 4 ◦C and permeabilized using a commercial buffer (Thermo Fisher Scientific). Samples were
incubated overnight with the appropriate primary antibodies: rabbit anti-TUBB3 (1:1000), mouse
anti-NES (1:500), rabbit anti-DCX (1µg/mL), rabbit anti-TH (1:200) and rabbit anti-DAT (1:200), then
washed with PBS, and incubated for 30 min with appropriate secondary antibodies Alexa Fluor® 488
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(1:1000), washed and, then, analyzed on a BD FACScan System (Becton-Dickinson, San Jose, CA, USA).
10,000 cells were examined. The results were analyzed using Weasel software v2.6.1.
2.11. Immunocytochemistry
For immunocytochemistry, cells were fixed with 4% paraformaldehyde for 15 min at room
temperature and permeabilized using 0.1% Triton X-100 (Sigma-Aldrich) diluted in PBS for 10 min.
To block unspecific epitopes, cells were incubated with 0.1% bovine serum albumin. Primary antibodies
(anti-TUBB3, 1:1000 and anti-TH, 1:200) were incubated overnight at 4 ◦C followed by incubation with
appropriate fluorescently labeled secondary antibodies, Alexa Fluor® 488 and 594 (1:1000) for 1 h at
room temperature. Finally, cell nuclei were counterstained with 4′,6-diamidino-2-phenylindole (DAPI)
(Sigma-Aldrich). Image acquisition was performed using a FLoidTM Cell Imaging Station (Thermo
Fisher Scientific).
2.12. ELISA
Dopamine/noradrenaline and acetylcholine measurements were performed using commercially
available dopamine/noradrenaline and Amplex Red Acetylcholine/Acetylcholinesterase ELISA kits.
Samples were collected and measured immediately according to manufacturer’s instruction. For the
analysis of dopamine/noradrenaline release, cell membrane depolarization was induced with 100 mM
KCl for 10 min. KCl-containing medium was replaced with fresh culture medium and cells were
incubated for another 6 h. Then, media and cells were collected and analyzed [33]. Protein levels were
analyzed in whole-cell lysates obtained using RIPA buffer.
2.13. Analysis of Oxidative Phosphorylation Function
Citrate synthase (CS) specific activity, protein amount, CIV specific activity and quantity, oxygen
consumption and mitochondrial protein synthesis were measured according to protocols previously
published [34,35].
2.14. Mouse Experiments
All animal procedures were carried out under Project License PI03/17, approved by the Ethic
Committee for Animal Experiments from the Universidad de Zaragoza. The care and use of animals
were performed accordingly with the Spanish Policy for Animal Protection RD53/2013, which meets
the European Union Directive 2010/63 on the protection of animals used for experimental and other
scientific purposes.
As previously mentioned, humans receive 1,200 mg LIN per day. The mouse equivalent dose,
calculated according to the body surface normalization method [36], would be 5 mg LIN per day,
well below the limit dose generally accepted in studies of toxicity in mice [37]. Between embryonic
days E8 and E15 (8 days), 8-week-old C57BL/6J pregnant mice were daily administered, either with
vehicle (methyl cellulose 1%), LIN 5 mg/day, uridine 70 mg/day or LIN plus uridine by oral gavage.
On embryonic day E16, pregnant dams were sacrificed by cervical dislocation and fetal brains were
obtained for further analysis.
2.15. Statistical Analysis
The statistical package StatView 5.0 was used to perform all the statistical analyses. Mann–Whitney
and Kruskal–Wallis non-parametric tests were used to compare parameters. To compare more than
two groups, post-hoc tests were also performed. All data were expressed as mean ± standard deviation
and number of independent experiments (N) and significance levels were set at p < 0.05 and the levels
indicated by the post-hoc tests.
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3. Results
3.1. OXPHOS Function and Neuronal Differentiation
Firstly, we studied the dopaminergic neuronal differentiation of human neuroblastoma SH-SY5Y
cells and compared it with that of hNSCs. Neuronal markers similarly increase with differentiation in
both cells, and this differentiation process was very specific for dopaminergic neurons (Figures S1–S5
and Table S1).
Then, we analyzed OXPHOS changes along neuronal differentiation. Despite the fact that the
changes in dopaminergic neuronal parameters after differentiation were similar in SH-SY5Y cells and
hNSCs, we detected large differences in OXPHOS variables after this process (Figure S6). However,
substantial differences in mitochondrial parameters after neuronal differentiation had been already
reported [8,38], even within SH-SY5Y cells [39–41]. Moreover, several studies reported that cells
harboring OXPHOS-related mutant genes were able to normally differentiate into neurons [10,42–46].
All these observations raise doubts about the role of OXPHOS in neural differentiation, although
these disparities could also be due to methodological differences [47].
3.2. OXPHOS Dysfunction and Dopaminergic Neuronal Differentiation
To corroborate the importance of OXPHOS function on dopaminergic neuronal differentiation,
we overexpressed OXPHOS-related mutant proteins in neuroblastoma SH-SY5Y cells (Figures S7–S9).
Then, we confirmed their effect on OXPHOS function and analyzed their dopaminergic neuronal
differentiation ability in similar conditions.
The levels of mtDNA, OXPHOS subunits and oxygen consumption were lower in SH-SY5Y cells
overexpressing the mutant POLG than the wild type (Figure 1A–C). Mutant cells showed reduced
TUBB3 and TH amount when compared with wild-type cells (Figure 1D).
The levels of OXPHOS subunits and oxygen consumption were lower in SH-SY5Y cells
overexpressing the mutant MRPS12 protein than in cells overexpressing the wild-type version
(Figure 1E,F). Cells overexpressing the mutant version showed reduced TUBB3 and TH amount when
compared with those overexpressing the wild-type version (Figure 1G).
Cells overexpressing the mutant version of UQCRFS1 did not show differences in OXPHOS
subunit levels, and only a mild reduction in oxygen consumption levels was found when compared
with those overexpressing the wild-type protein (Figure 1H,I). However, mutant cells showed reduced
TUBB3 and TH amount when compared with wild-type cells (Figure 1J).
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UQCRC2, complex III (CIII) subunit; SDHB, complex II (CII) subunit; p.MT-CO2, complex IV (CIV) 
subunit; and NDUFB8, complex I (CI) subunit. Molecular weights are also indicated. (C) Oxygen 
consumption. Dashed line (100%) represents the mean value of undifferentiated TWT cells. The bar 
indicates the mean value and standard deviation (N = 3) of undifferentiated TM cells. *, p < 0.05 
(versus TWT cells, Mann–Whitney). (D) Dopaminergic neuronal differentiation. FI, fluorescence 
intensity (flow cytometry) of dopaminergic neuronal markers TUBB3 and TH. Dashed line (100%) 
represents the mean values of undifferentiated TWT or TM cells. Bars indicate the mean values and 
standard deviations (N = 3) of differentiated TWT or TM cells. *, p < 0.05 (versus undifferentiated 
TWT or TM cells, Mann–Whitney). &, p < 0.05 (versus differentiated TWT cells, Mann–Whitney). (E–
G) Wild-type (TWT) or Mutant (TM) MRPS12 transfected cells. (E) Levels of representative subunits 
of OXPHOS complexes. See panel B. (F) Oxygen consumption. (N = 3). See panel C. (G) 
Dopaminergic neuronal differentiation. (N = 6). See panel D. (H–J) Wild-type (TWT) or Mutant (TM) 
Figure 1. Effects of the overexpression of OXPH S-related mutant proteins on neuroblastoma SH-SY5Y
cells. (A–D) Wild-type (TWT) or Mutant (TM) POLG transfected cells. (A) Mitochondrial DNA
(mtDNA) levels. Dashed line (100%) represents the mean value of undifferentiated TWT cells. The bar
indicates the mean value and standard deviation (independent experiments, N = 4) of undifferentiated
TM cells. * p < 0.05 (versus TWT cells, Mann–Whitney). (B) Levels of representative subunits of
OXPHOS complexes. NT, non-transfected cells. ATP5A, complex V (CV) subunit; UQCRC2, complex
III (CIII) s bunit; SDHB, complex II (CII) subunit; p.MT-CO2, complex IV (CIV) subunit; and NDUFB8,
complex I (CI) subunit. Molecular weight are also indic ted. (C) Oxygen consumption. Dashed line
(100%) represents the mean value of undifferentiated TWT cells. The bar indicates the mean value and
standard deviation (N = 3) of undifferentiated TM cells. * p < 0.05 (versus TWT cells, Mann–Whitney).
(D) Dopaminergic neuronal differentiation. FI, fluorescence intensity (flow cytometry) of dopaminergic
neuronal markers TUBB3 and TH. Dashed line (100%) represents the mean values of undifferentiated
TWT or TM cells. Bars indicate the mean values and standard deviations (N = 3) of differentiated
TWT or TM cells. * p < 0.05 (versus undifferenti ted TWT or TM cell , Mann–Whitney). & p < 0.05
(versus differentiated TWT cells, M n–Whitney). (E–G) Wild- ype TWT) or Mutant (TM) MRPS12
transfected cells. (E) Levels of representative subunits of OXP OS complexes. See panel B. (F) Oxygen
consumption. (N = 3). See panel C. (G) Dopaminergic neuronal differentiation. (N = 6). See panel
D. (H–J) Wild-type (TWT) or Mutant (TM) UQCRFS1 transfected cells. (H) Levels of representative
subunits of OXPHOS complexes. See panel B. (I) Oxygen consumption. (N = 6). See panel C.
(J) Dopaminergic neuronal differentiation. (N = 3). See panel D.
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3.3. OXPHOS Xenobiotics and Dopaminergic Neuronal Differentiation
It was reported that one PD-inducing xenobiotic, the CI inhibitor 1-methyl-4-phenylpyridinium
ion (MPP+), also interfered with mtDNA replication by destabilization of the mtDNA D-loop [48].
The inhibition of mtDNA replication, the translation of mtDNA-encoded mRNAs or respiratory complex
activities by chemical compounds (AZT, LIN, ATO) might cause similar effects on dopaminergic
neuronal differentiation as overexpressing of OXPHOS-related mutant proteins (POLG, MRPS12,
UQCRFS1). At the concentrations and times we used, these OXPHOS xenobiotics did not affect the
proliferation of SH-SY5Y cells.
Azidothymidine. In SH-SY5Y cells, the presence of 5 µM AZT did not decrease mtDNA levels or
the OXPHOS complex subunits, but reduced oxygen consumption (Figure 2A–C). Similarly, it was
reported that, at higher AZT concentrations, there was no reduction in mtDNA amount in other
cultured cells [49]. Moreover, it was published that, at these high AZT concentrations, mtDNA-encoded
subunit levels and most respiratory complex activities were not decreased in human hepatoma HepG2
cells [49]. However, it was informed that, in rat H9c2 cardiomyocytes, oxygen consumption was
reduced and, in mouse primary cortical neurons, AZT treatment decreased mitochondrial respiration
without any effect on mtDNA levels [50,51]. During our differentiation process, the increase in TUBB3
and TH levels was significantly lower in 5-µM AZT-treated cells (Figure 2D). Similar to this result,
it has been previously shown that treatment with 10 µM AZT induced a significant decreases of MAP-2
and synaptophysin in rat cerebrocortical cells after 7 days [52].
Linezolid. We analyzed the LIN effect on OXPHOS function of SH-SY5Y cells. Mitochondrial
protein synthesis and the amount of the p.MT-CO1 subunit from CIV were moderately reduced by
40 µM LIN (Figure 2E,F). However, oxygen consumption was significantly decreased (Figure 2G).
Some of these parameters had been earlier reported decreased in LIN treated human osteosarcoma
143B cybrids, hASCs, and adipocyte-differentiated hASCs [16,17,25]. The increase in TUBB3 and TH
levels was significantly lower in 40 µM LIN-treated cells (Figure 2H). It was previously shown that,
another mitochondrial protein synthesis inhibitor, chloramphenicol prevented neurite outgrowth
and synaptophysin increase in C1300 murine neuroblastoma cells [53], reduced neurite length in rat
PC12-ND6 cells and the frequency of stage 3 mouse hippocampal neurons [54], and reduced mouse
primary cortical neuron differentiation [55].
Atovaquone. We also studied the ATO effect on OXPHOS function of these cells. The p.MT-CO1
subunit levels from CIV were not affected by 0.5 µM ATO, but oxygen consumption was significantly
reduced (Figure 2I,J). The increase in TUBB3 and TH levels was significantly lower in 0.5µM ATO-treated
cells (Figure 2K).
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azidothymidine (AZT). (A) Mitochondrial DNA (mtDNA) levels. Dashed line (100%) represents
the mean value of untreated undifferentiated (U) or differentiated (D) cells. Bars indicate the mean
values and standard deviations (independent experiments, N = 2) of AZT-treated U or D cells.
(B) Levels of the p.MT-CO1 subunit from complex IV (CIV) in untreated and AZT-treated (+AZT)
cells. The nDNA-encoded complex II (CII) subunit SDHA as used to check the protein loading.
Molecular weights are indicated. M, U, D code for molecular weight marker, undifferentiated (U) and
differentiated (D) cells, respectively. (N = 3). (C) Oxygen consumption. Dashed line (100%) represents
the mean value of untreated or treated undifferentiated (U) cells. Bars indicate the mean values and
standard devi tio s (N = 3) of untreated (C) or treated (+AZT) differentiated (D) cells. * p < 0.05 (versus
U cells, Mann–Whitney). & p < 0.05 (versus untreated D cells, Mann–Whitney). (D) Dopaminergic
neuronal differentiation. FI, fluorescence intensity (flow cytometry) of dopaminergic neuronal markers
TUBB3 and TH. Dashed line (100%) represents the mean value of undifferentiated (U) cells. Bars indicate
the mean values and standa d deviations (N = 3) of untreated (C) a d treated (+AZT) differentiated (D)
cells. * p < 0.05 (versus U cells, Mann–Whitney). & p < 0.05 (versus untreated D cells, Mann–Whitney).
E-H) Treatment with linezolid (LIN). (E) Representative image of gels for mitochondrial protein
synthesis analysis. Gels showing the loading control and electrophoretic patterns of mitochondrial
translation products from untreated and treate (+LIN) cells are included. M, U, D code for molecular
weight marker, undifferentiated (U) and differentiated (D) cells, respectively. Proteins p.MT-ND1-6
and p.MT-ND4L are CI mtDNA-encoded subunits; p.MT-CYB is a mtDNA-encoded subunit from
CIII; p.MT-CO1-3 are mtDNA-encoded subunits from CIV; and p.MT-ATP6,8 are mtDNA-encoded
subunits from CV. (N = 2). (F) Levels of p.MT-CO1 subunit in untreated and LIN-treated (+LIN) cells.
β-ACTIN was used to check the protein loading. (N = 2). See panel B. (G) Oxygen consumption.
(N = 3). See panel C. (H) Dopaminergic neuronal differentiation. (N = 3). See panel D. (I–K) Treatment
with atovaquone (ATO). (I) Levels of p.MT-CO1 subunit in untreated and ATO-treated (+ATO) cells.
(N = 3). See panels B and F. (J) Oxygen consumption. (N = 3). See panel C. (K) Dopaminergic neuronal
differentiation. (N = 4). See panel D.
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3.4. High Glucose or Uridine Compensate OXPHOS-Dysfunction Effects on Dopaminergic Neuronal
Differentiation
All previous results support an important role for OXPHOS function on dopaminergic neuronal
differentiation. In order to better understand the studies reporting normal neuronal differentiation in
cells harboring OXPHOS-related mutant genes [10,42–46], we have studied a neuroblastoma SH-SY5Y
rho0 cell line and, therefore, with no OXPHOS function.
Neuroblastoma SH-SY5Y rho0 cell line. We confirmed the absence of mtDNA in a neuroblastoma
SH-SY5Y rho0 cell line (Figure S10). As previously commented, rho0 cells require high glucose and
uridine to survive. These cells with no mtDNA or OXPHOS function were able to differentiate into
dopaminergic neurons, as determined by neurite production and increased TUBB3, NES, MAP2,
TH and DAT levels (Figure 3A–C). Another neuroblastoma SH-SY5Y rho0 cell line generated in our
laboratory was also able to differentiate into dopaminergic neurons (data not shown).
If rho0 cells, without OXPHOS function, differentiate into dopaminergic neurons, perhaps
OXPHOS xenobiotics, such as AZT, LIN and ATO, affect differentiation to dopaminergic neuron
through a mechanism not involving OXPHOS function. To check this possibility, we differentiated
SH-SY5Y rho0 cells in the presence of 40 µM LIN. There were no significant differences between
LIN-untreated and treated differentiated rho0 cells. They were able to undergo dopaminergic neuronal
differentiation (Figure 3B,C). In fact, it was previously shown that the oxazolidinone eperezolid, similar
to LIN, caused no growth inhibition of rho0 cells, although it affected parental cells [56]. Besides, it had
been also reported that ATO suppressed apoptosis in parental cells but not rho0 cells [29]. These results
confirm that the effect of these drugs was carried out through an inhibition of the OXPHOS function.
Rho0 medium recovers dopaminergic neuronal differentiation of OXPHOS-dysfunctional
cells. Similar to rho0 cells, cells overexpressing a mutant MRPS12 protein, 40 µM LIN-treated cells, or
cells overexpressing a mutant MRPS12 protein treated with 40 µM LIN were able to differentiate into
dopaminergic neurons when the differentiation is induced in rho0 medium containing high glucose
(25 mM) and uridine (200 µM) (Figure 3D–F).
High glucose recovers dopaminergic neuronal differentiation of OXPHOS-dysfunctional cells.
As OXPHOS-dysfunctional SH-SY5Y cells were able to differentiate into dopaminergic neurons in
differentiation medium supplemented with 25 mM glucose plus 200 µM uridine, we checked if this
glucose concentration, without additional uridine, was enough to rescue the neuronal differentiation
of cells overexpressing a mutant MRPS12 protein, 40 µM LIN-treated cells, or cells overexpressing
a mutant MRPS12 protein treated with 40 µM LIN. Twenty-five mM glucose was able to recover
dopaminergic neuronal differentiation of all these cells (Figure 3G–I). However, 25 mM glucose in
medium with dialyzed serum was able to slightly increase TUBB3, but not TH, levels of LIN-treated
cells (data not shown).
High uridine recovers dopaminergic neuronal differentiation of OXPHOS-dysfunctional cells.
Rho0 cells also need uridine to survive and proliferate [19], and uridine is lost when serum is dialyzed.
Possibly uridine was also required for the dopaminergic neuronal differentiation of SH-SY5Y rho0 cells.
Two-hundred µM uridine was able to recover dopaminergic neuronal differentiation of cells
overexpressing a mutant MRPS12 protein, 40 µM LIN-treated cells, or cells overexpressing a mutant
MRPS12 protein treated with 40 µM LIN (Figure 3J–L). In fact, it has been previously shown that
chick embryo cells were resistant to the growth-inhibitory effects of another ribosomal antibiotic,
chloramphenicol, when cultured in the presence of uridine [57]. It was also reported that, after 4 days of
uridine exposure, PC12 rat pheochromocytoma cells differentiated by nerve growth factor significantly
and dose-dependently increased the number of neurites per cell. This rise was accompanied by increases
in neurite branching and in levels of the neurite proteins neurofilament M and 70. It has also been
found that uridine treatment also increases intracellular levels of cytidine triphosphate, which suggests
that uridine may affect neurite outgrowth by enhancing phosphatidylcholine synthesis [58,59].
Cells 2019, 8, 1407 12 of 20
Cells 2019, 8, x FOR PEER REVIEW 12 of 20 
 
days of uridine exposure, PC12 rat pheochromocytoma cells differentiated by nerve growth factor 
significantly and dose-dependently increased the number of neurites per cell. This rise was 
accompanied by increases in neurite branching and in levels of the neurite proteins neurofilament M 
and 70. It has also been found that uridine treatment also increases intracellular levels of cytidine 
triphosphate, which suggests that uridine may affect neurite outgrowth by enhancing 
phosphatidylcholine synthesis [58,59]. 
 
Figure 3. Effects of the high glucose and/or uridine on dopaminergic neuronal differentiation of 
OXPHOS-dysfunctional cells. (A–C) Neuroblastoma SH-SY5Y rho0 cells. (A) Neuron-differentiated 
. Effects f t i / ff
f cti al ll . ( ) ff
rho0 cells. Arrowheads indicate neurites. (B) Dopaminergic neuronal differentiation with (+LIN) or
without (-LIN) linezolid. FI, fluorescence intensity (flow cytometry) of dopaminergic neuronal markers
TUBB3, NESTIN, TH and DAT. Dashed line (100%) represents the mean value of undifferentiated (U)
rho0 cells. Bars indicate the mean values and standard deviations (independent experiments, N = 3)
Cells 2019, 8, 1407 13 of 20
of differentiated (D) rho0 cells. * p < 0.05 (versus U rho0 cells, Mann–Whitney). (C) Levels of
dopaminergic neuronal markers in untreated (−LIN)- or treated (+LIN)-undifferentiated (U) and
differentiated (D) rho0 cells. (N = 2). β-ACTIN was used to check the protein loading. (D–F) Neuronal
differentiation of SH-SY5Y rho+ cells in high glucose (GLC) and uridine (Ur) media. (D) SH-SY5Y rho+
cells overexpressing wild-type (TWT) or mutant (TM) MRPS12 protein. FI, fluorescence intensity (flow
cytometry) of dopaminergic neuronal markers TUBB3 and TH. Dashed line (100%) represents the mean
value of undifferentiated (U) cells. Bars indicate the mean values and standard deviations (N = 3) of
differentiated (D) cells. * p < 0.05 (versus U cells, Mann–Whitney). & p < 0.05 (versus TWT D cells,
Mann–Whitney). (E) Untreated (C) or linezolid treated (+LIN) SH-SY5Y rho+ cells. FI, fluorescence
intensity (flow cytometry) of dopaminergic neuronal markers TUBB3 and TH. Dashed line (100%)
represents the mean value of undifferentiated (U) cells. Bars indicate the mean values and standard
deviations (N = 3) of differentiated (D) cells. * p < 0.05 (versus U cells, Mann–Whitney). (F) Linezolid
(LIN)-treated SH-SY5Y rho+ cells overexpressing wild-type (TWT) or mutant (TM) MRPS12 protein. FI,
fluorescence intensity (flow cytometry) of dopaminergic neuronal markers TUBB3 and TH. Dashed
line (100%) represents the mean value of undifferentiated (U) cells. Bars indicate the mean values
and standard deviations of differentiated (D) cells. * p < 0.05 (versus U cells, Mann–Whitney). G-I)
Neuronal differentiation of SH-SY5Y rho+ cells in high glucose (GLC) media. (G) SH-SY5Y rho+ cells
overexpressing wild-type (TWT) or mutant (TM) MRPS12 protein. (N = 3). See panel D. (H) Untreated
(C) or linezolid treated (+LIN) SH-SY5Y rho+ cells. (N = 3). * p < 0.05 (versus U cells). # p < 0.05
(versus untreated D cells, Mann–Whitney). See panel E. (I) Linezolid (LIN)-treated SH-SY5Y rho+ cells
overexpressing wild-type (TWT) or mutant (TM) MRPS12 protein. (N = 3). * p < 0.05 (versus U cells).
$ p < 0.05 (versus LIN-treated TWT D cells, Mann–Whitney). See panel F. (J–L) Neuronal differentiation
of SH-SY5Y rho+ cells in high uridine (Ur) media. (J) SH-SY5Y rho+ cells overexpressing wild-type
(TWT) or mutant (TM) MRPS12 protein. (N = 3). See panel D. (K) Untreated (C) or linezolid treated
(+LIN) SH-SY5Y rho+ cells. (N = 3). See panel E and H. (L) Linezolid (LIN)-treated SH-SY5Y rho+ cells
overexpressing wild-type (TWT) or mutant (TM) MRPS12 protein. (N = 3). See panel F.
3.5. Effect of Prenatal Exposure to Linezolid on Mouse Brain
All the results shown above indicate that OXPHOS function is relevant for dopaminergic neuronal
differentiation. This process is part of the neurogenesis, i.e., the birth of new neurons from stem
cells. In adult substantia nigra, neurogenesis remains controversial [60]. This process mainly occurs
during development of the nervous system in early life [61]. Thus, in humans, dopaminergic neurons
from substantia nigra pars compacta are generated from the early fifth (5.3) through the middle part
of the seventh (7.0) week after fertilization [62]. The specification and differentiation of midbrain
dopaminergic neurons in mice occurs between embryonic days 8–15 [62].
We supplied pregnant mice daily between embryonic days E8 and E15 with vehicle, 5 mg LIN,
70 mg uridine or 5 mg LIN plus 70 mg uridine. The fetus brains were analyzed on embryonic day E16.
There were no significant differences in CIV activity or quantity; in dopamine concentration; in TH or
DAT amount; in En1, Nr4a2 and Pitx3 mRNA levels; or in miRNA 124, 132 or 133 levels (Figure S11).
However, LIN increased global DNA methylation in fetal brain (Figure 4) and, remarkably, uridine
was able to reduce it.
The PD incidence peak occurs between the age of 70 to 79 years. This human age is equivalent
to 20 months of age in mice [63]. Hence, older mice should be analyzed to appreciate LIN effects on
their brain. However, the early effect in methylation we have observed might suggest that the early
exposure to OXPHOS xenobiotics could interfere with developmental programming of nigrostriatal
neurons [64]. Thus, the long-lasting modification of global DNA methylation levels might be the
connection between these two distant life events: prenatal exposure and old age PD manifestation.
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4. Discussion
As we have shown, some pharmaceutical drugs inhibiting OXPHOS function reduce dopaminergic
neuronal differentiation. The exposure to some of these drugs is not rare. For example, NRTIs are used
to prevent mother-to-child HIV transmission. Perinatal HIV transmission is virtually zero in mothers
who start NRTIs before conception [65]. In fact, the most recent US guidelines for preconception
counseling suggest starting NRTIs when planning pregnancy [66]. Nevertheless, it has been shown
that pregnant mice exposed to NRTI in doses that correspond to those used for pregnant HIV-positive
women significantly decreased the inducible neurogenesis potential [24]. In utero, AZT exposure
perturbs neurogenesis among neural stem/progenitor cells and a short-term AZT regimen in adult
mice suppresses subependymal zone neurogenesis [24]. Moreover, some children (0.3%) exposed to
these analogues during the perinatal period are at risk of a neurological syndrome, including motor
abnormalities, associated with persistent OXPHOS dysfunction during the first 18 months [67].
ATO is an effective drug for malaria prophylaxis and treatment that is not currently recommended
for use by pregnant women due to insufficient data on its safety in pregnancy. Besides that, the use of
anti-malarial in pregnancy is likely to occur before the woman in question knows of her pregnancy [68],
even in the first weeks (3 to 8) after conception [69].
Tuberculosis prevalence in pregnant women is substantial [70], and is associated with poor
outcomes [71]. Because of that, ideally all pregnant women should start the treatment as soon as
possible. LIN is one of the second-line drugs used for treatment MDR-TB in pregnancy. However,
according to the US Food and Drug Administration, LIN is a pregnancy class C agent, meaning that
animal studies demonstrate a risk and there are no human studies [71]. Here, we show that LIN
affects dopaminergic neuronal differentiation of neuroblastoma SH-SY5Y cells, but does not affect these
parameters in mouse fetal brains. However, global DNA methylation in fetal brains was altered.
Uridine might complement the administration of these drugs during the first trimester of
pregnancy. Uridine inhibited negative effects of LIN on dopaminergic neuronal differentiation and
also reduced global DNA methylation. It was previously shown that, in particular conditions, lack of
OXPHOS function is not an obstacle for cell differentiation. Thus, a human rhabdomyosarcoma RD
rho0 cell line retained the ability to differentiate into myotubes with the expression of muscle specific
isoenzymes, such as creatine kinase M (CK-M) [72]. Differentiation along the monocyte/macrophage
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pathway was very pronounced in the HL60 human promyelocytic leukemia rho0 cell line [73]. There is
another report showing that neuroblastoma SH-SY5Y rho0 cells under neural differentiation protocol
expressed long neurites with secretory granules and NSE [42]. Here, we also report an increase
in TUBB3, MAP2, TH and DAT levels during neuroblastoma SH-SY5Y rho0 cell differentiation.
The common conditions for all these differentiation studies of rho0 cells are the presence of high
glucose and uridine in the differentiation media. Neuronal differentiation requires the production
of large amounts of plasma membrane (plasmalemma). Vulnerable nigral dopaminergic neurons
differ from other neurons by having a considerably more complex axonal arborization [1]. Therefore,
the formation of axons and dendrites and maintenance of the neuron’s vastly expanded surface
require a continuous membrane synthesis [74]. Glycoproteins, glycolipids and phospholipids are
major plasmalemma components. Uridine triphosphate (UTP) and glucose are important metabolites
in the synthesis of these glycosylated substances. It is possible that the recovery of the capacity
of differentiating into dopaminergic neuron after glucose supply in OXPHOS-dysfunctional cells is
due to the allocation of glucose to energy-generating glycolysis and to pathways of glycoconjugate
synthesis [75]. Moreover, UTP is a precursor of cytidine triphosphate (CTP), which is important
in the synthesis of phospholipids [59]. Very interestingly, it has been reported that triacetyluridine,
with a greater oral bioavailability than uridine, significantly attenuated MPTP-induced depletion of
striatal dopamine and loss of TH-positive neurons in mouse substantia nigra [76]. Potassium-evoked
dopamine release was significantly greater among uridine monophosphate (UMP)-treated rats and the
levels of neurofilament-70 and neurofilament-N proteins, biomarkers of neurite outgrowth, increased
with UMP consumption [58]. UMP treatment reduced ipsilateral rotations and significantly elevated
rat striatal dopamine, TH activity and protein, and synapsin-1 protein [77]. Thus, uridine could be used
as a protective agent against OXPHOS xenobiotics provided during pregnancy, when dopaminergic
neuronal differentiation is taking place. It could also be beneficial during pregnancy of women
harboring mtDNA pathologic mutations.
The decreased dopaminergic neurogenesis could be important in the development of PD [18].
Here, we have demonstrated that the exposure to AZT, LIN or ATO reduces dopaminergic neurogenesis.
Therefore, early contact with these drugs might be a risk factor for developing PD.
5. Conclusions
AZT, LIN and ATO, at concentrations found in human blood, reduce dopaminergic neuronal
differentiation of neuroblastoma SH-SY5Y cells and LIN increases global DNA methylation of mouse
fetal brains. Uridine inhibits these effects and could be considered during the treatment with these drugs.
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